150 related articles for article (PubMed ID: 32020517)
41. Changes in the neutrophil-to-lymphocyte ratio predict the prognosis of patients with advanced hepatocellular carcinoma treated with sorafenib.
Hong YM; Yoon KT; Hwang TH; Heo J; Woo HY; Cho M
Eur J Gastroenterol Hepatol; 2019 Oct; 31(10):1250-1255. PubMed ID: 30925530
[TBL] [Abstract][Full Text] [Related]
42. Vessels That Encapsulate Tumor Clusters (VETC) Pattern Is a Predictor of Sorafenib Benefit in Patients with Hepatocellular Carcinoma.
Fang JH; Xu L; Shang LR; Pan CZ; Ding J; Tang YQ; Liu H; Liu CX; Zheng JL; Zhang YJ; Zhou ZG; Xu J; Zheng L; Chen MS; Zhuang SM
Hepatology; 2019 Sep; 70(3):824-839. PubMed ID: 30506570
[TBL] [Abstract][Full Text] [Related]
43. Methylene tetrahydrofolate reductase (MTHFR) and vascular endothelial growth factor (VEGF) polymorphisms in Brazilian patients with Hepatitis C virus (HCV)-related hepatocellular carcinoma (HCC).
Carvalho SCR; Vasconcelos LRS; Fonseca LD; Carmo RF; Tomitão MT; Aroucha DCBL; Pereira LMMB; Stefano JT; Ribeiro-Júnior U; Oliveira CP; Carrilho FJ
Clinics (Sao Paulo); 2021; 76():e2881. PubMed ID: 34644732
[TBL] [Abstract][Full Text] [Related]
44. Influence of vascular endothelial growth factor single nucleotide polymorphisms on non-small cell lung cancer tumor angiogenesis.
Maeda A; Nakata M; Yasuda K; Yukawa T; Saisho S; Okita R; Hirami Y; Shimizu K
Oncol Rep; 2013 Jan; 29(1):39-44. PubMed ID: 23064377
[TBL] [Abstract][Full Text] [Related]
45. Rs9679162 genotype predicts prognosis of real-world advanced hepatocellular carcinoma treated by sorafenib.
Lin CL; Chien RN; Chen LW; Chu YD; Yeh CT
Cancer Biomark; 2023; 36(3):251-266. PubMed ID: 36938726
[TBL] [Abstract][Full Text] [Related]
46. Genetic polymorphisms of proangiogenic factors seem to favor hepatocellular carcinoma development in alcoholic cirrhosis.
Machado MV; Janeiro A; Miltenberger-Miltenyi G; Cortez-Pinto H
Eur J Gastroenterol Hepatol; 2014 Apr; 26(4):438-43. PubMed ID: 24445728
[TBL] [Abstract][Full Text] [Related]
47. HIF-1α-induced RIT1 promotes liver cancer growth and metastasis and its deficiency increases sensitivity to sorafenib.
Song Z; Liu T; Chen J; Ge C; Zhao F; Zhu M; Chen T; Cui Y; Tian H; Yao M; Li J; Li H
Cancer Lett; 2019 Sep; 460():96-107. PubMed ID: 31247273
[TBL] [Abstract][Full Text] [Related]
48. Bclaf1 promotes angiogenesis by regulating HIF-1α transcription in hepatocellular carcinoma.
Wen Y; Zhou X; Lu M; He M; Tian Y; Liu L; Wang M; Tan W; Deng Y; Yang X; Mayer MP; Zou F; Chen X
Oncogene; 2019 Mar; 38(11):1845-1859. PubMed ID: 30367150
[TBL] [Abstract][Full Text] [Related]
49. PFKFB3/HIF-1α feedback loop modulates sorafenib resistance in hepatocellular carcinoma cells.
Long Q; Zou X; Song Y; Duan Z; Liu L
Biochem Biophys Res Commun; 2019 Jun; 513(3):642-650. PubMed ID: 30981500
[TBL] [Abstract][Full Text] [Related]
50. Increased cumulative doses and appearance of hand-foot skin reaction prolonged progression free survival in sorafenib-treated advanced hepatocellular carcinoma patients.
Chang WT; Lu SN; Rau KM; Huang CS; Lee KT
Kaohsiung J Med Sci; 2018 Jul; 34(7):391-399. PubMed ID: 30063012
[TBL] [Abstract][Full Text] [Related]
51. Survival Benefit of Experience of Liver Resection for Advanced Recurrent Hepatocellular Carcinoma Treated with Sorafenib: A Propensity Score Matching Analysis.
Hsueh KC; Lee CC; Huang PT; Liang CY; Yang SF
Curr Oncol; 2023 Mar; 30(3):3206-3216. PubMed ID: 36975456
[TBL] [Abstract][Full Text] [Related]
52. The role of LDH serum levels in predicting global outcome in HCC patients treated with sorafenib: implications for clinical management.
Faloppi L; Scartozzi M; Bianconi M; Svegliati Baroni G; Toniutto P; Giampieri R; Del Prete M; De Minicis S; Bitetto D; Loretelli C; D'Anzeo M; Benedetti A; Cascinu S
BMC Cancer; 2014 Feb; 14():110. PubMed ID: 24552144
[TBL] [Abstract][Full Text] [Related]
53. Prognostic impact of pERK in advanced hepatocellular carcinoma patients treated with sorafenib.
Chen D; Zhao P; Li SQ; Xiao WK; Yin XY; Peng BG; Liang LJ
Eur J Surg Oncol; 2013 Sep; 39(9):974-80. PubMed ID: 23845703
[TBL] [Abstract][Full Text] [Related]
54. Lower Serum Sodium Levels Are Associated with the Therapeutic Effect of Sorafenib on Hepatocellular Carcinoma.
Kegasawa T; Sakamori R; Maesaka K; Yamada R; Tahata Y; Urabe A; Kodama T; Hikita H; Imanaka K; Ohkawa K; Hiramatsu N; Oshita M; Yamada Y; Inada M; Yakushijin T; Imai Y; Tatsumi T; Takehara T
Dig Dis Sci; 2021 May; 66(5):1720-1729. PubMed ID: 32556820
[TBL] [Abstract][Full Text] [Related]
55. Hypoxia-inducible factor-1 alpha, in association with inflammation, angiogenesis and MYC, is a critical prognostic factor in patients with HCC after surgery.
Dai CX; Gao Q; Qiu SJ; Ju MJ; Cai MY; Xu YF; Zhou J; Zhang BH; Fan J
BMC Cancer; 2009 Dec; 9():418. PubMed ID: 19948069
[TBL] [Abstract][Full Text] [Related]
56. Augmentation of IFN-γ+ CD8+ T cell responses correlates with survival of HCC patients on sorafenib therapy.
Kalathil SG; Hutson A; Barbi J; Iyer R; Thanavala Y
JCI Insight; 2019 Aug; 4(15):. PubMed ID: 31391334
[TBL] [Abstract][Full Text] [Related]
57. Cyclin-dependent kinase 5 stabilizes hypoxia-inducible factor-1α: a novel approach for inhibiting angiogenesis in hepatocellular carcinoma.
Herzog J; Ehrlich SM; Pfitzer L; Liebl J; Fröhlich T; Arnold GJ; Mikulits W; Haider C; Vollmar AM; Zahler S
Oncotarget; 2016 May; 7(19):27108-21. PubMed ID: 27027353
[TBL] [Abstract][Full Text] [Related]
58. Microvascular Invasion as a Predictor of Response to Treatment with Sorafenib and Transarterial Chemoembolization for Recurrent Intermediate-Stage Hepatocellular Carcinoma.
Peng Z; Chen S; Xiao H; Wang Y; Li J; Mei J; Chen Z; Zhou Q; Feng S; Chen M; Qian G; Peng S; Kuang M
Radiology; 2019 Jul; 292(1):237-247. PubMed ID: 31135299
[TBL] [Abstract][Full Text] [Related]
59. Anti-PD-1 combined sorafenib versus anti-PD-1 alone in the treatment of advanced hepatocellular cell carcinoma: a propensity score-matching study.
Chen SC; Huang YH; Chen MH; Hung YP; Lee RC; Shao YY; Chao Y
BMC Cancer; 2022 Jan; 22(1):55. PubMed ID: 35016637
[TBL] [Abstract][Full Text] [Related]
60. Are we SHARP enough? The importance of adequate patient selection in sorafenib treatment for hepatocellular carcinoma.
Labeur TA; Ten Cate DWG; Bart Takkenberg R; Azahaf H; van Oijen MGH; van Delden OM; de Man RA; van Vugt JLA; IJzermans JNM; Eskens FALM; Klümpen HJ
Acta Oncol; 2018 Nov; 57(11):1467-1474. PubMed ID: 29943624
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
